The Live Biotherapeutic Products And Microbiome Contract Manufacturing Market Size is valued at 230.8 Million in 2024 and is predicted to reach 1,456.9 Million by the year 2034 at a 18.1% CAGR during the forecast period for 2025-2034
Key Industry Insights & Findings from the Report:
The Human Microbiome is the group of loads of microbes living on and in the human body. The microbiomes are found, for example, in the skin, gut, mouth, and vagina. A live biotherapeutic product comprises a live microorganism used for the cure or treatment and prevention of disease. The live biotherapeutic industry is experiencing enormous research and development activities to develop products for various diseases and applications.
Till now, about 200 companies are developing microbiome-based therapies anticipated to treat an extensive range of severe diseases, with big pharmaceutical companies showing augmented interest by associating with early innovators. Most of the clinical treatment is under the preclinical stage, various are under clinical development, and about 15 are in phase II/III trials of development. The commercialization of these products in the coming years is expected to generate a huge potential for the growth of the market over the estimated timeframe. However, the lack of a satisfactory manufacturing capacity of the innovators may significantly hinder the market's growth. Additionally, lack of the essential industry standards associated with live biotherapeutics manufacturing, batch-to-batch reliability-related concerns, lack of infrastructure, and uncertainties related to product approval and regulatory review are some of the factors affecting market growth substantially. However, a growing number of deals among various developers for contract manufacturing is projected to generate immense opportunities for the market's growth globally.
The Global Live Biotherapeutic Products and Microbiome Contract Manufacturing Market is segmented on the basis of type of services, the scale of operation, and application. Based on the type of services, the market is segmented into Development Services, Manufacturing Services, and Others (Regulatory expertise and support, Quality Control and Assurance). Based on the scale of operation, the market is categorized into, preclinical scale operations, clinical scale operations, and commercial-scale operations. Also, in case of applications segment it is catagorised as C.difficle, Crohns disease, IBS, Diabetes and Others. Based on the region, the market is studied across North America, Asia-Pacific, Europe, and LAMEA.
Live Biotherapeutic Products And Microbiome Contract Manufacturing Market Report Scope
| Report Attribute | Specifications |
| Market Size Value In 2024 | USD 230.8 Million |
| Revenue Forecast In 2034 | USD 1,456.9 Million |
| Growth Rate CAGR | CAGR of 18.1 % from 2025 to 2034 |
| Quantitative Units | Representation of revenue in US$ Million and CAGR from 2025 to 2034 |
| Historic Year | 2021 to 2024 |
| Forecast Year | 2025-2034 |
| Report Coverage | The forecast of revenue, the position of the company, the competitive market structure, growth prospects, and trends |
| Segments Covered | By Type of Services, Scale of operations, and application |
| Regional Scope | North America; Europe; Asia Pacific; Latin America; Middle East & Africa |
| Country Scope | U.S.; Canada; Germany; China; Japan; Brazil; Mexico; the UK; France; Italy; Spain; Japan; India; South Korea; Southeast Asia |
| Competitive Landscape | Quay Pharmaceuticals, Cerbios-Pharma SA, List Biological Labs, Inc., Arranta Bio (Acquired by Recipharm), BacThera, Wacker Biotech, Biose Industrie, Wacker Biotech and Other prominent players |
| Customization Scope | Free customization report with the procurement of the report, Modifications to the regional and segment scope. Particular Geographic competitive landscape. |
| Pricing And Available Payment Methods | Explore pricing alternatives that are customized to your particular study requirements. |
Chapter 1. Methodology and Scope
1.1. Research Methodology
1.2. Research Scope & Assumptions
Chapter 2. Executive Summary
Chapter 3. Global Live Biotherapeutic Products And Microbiome Contract Manufacturing Market Snapshot
Chapter 4. Global Live Biotherapeutic Products And Microbiome Contract Manufacturing Market Variables, Trends & Scope
4.1. Market Segmentation & Scope
4.2. Drivers
4.3. Challenges
4.4. Trends
4.5. Investment and Funding Analysis
4.6. Industry Analysis – Porter’s Five Forces Analysis
4.7. Competitive Landscape & Market Share Analysis
4.8. Impact of Covid-19 Analysis
Chapter 5. Market Segmentation 1: By Type of Services Estimates & Trend Analysis
5.1. By Type of Services & Market Share, 2024 & 2034
5.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2021 to 2034 for the following By Type of Services:
5.2.1. Development Services
5.2.2. Manufacturing Services
5.2.3. Others (Regulatory expertise and support, Quality Control and Assurance)
Chapter 6. Market Segmentation 2: By Scale of Operations Estimates & Trend Analysis
6.1. By Scale of Operations & Market Share, 2024 & 2034
6.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2021 to 2034 for the following By Scale of Operations:
6.2.1. Preclinical Scale Operations
6.2.2. Clinical Scale Operations
6.2.3. Commercial Scale Operations
Chapter 7. Market Segmentation 3: By Application Estimates & Trend Analysis
7.1. By Application & Market Share, 2024 & 2034
7.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2021 to 2034 for the following By Application:
7.2.1. C.difficle
7.2.2. Crohns disease
7.2.3. IBS
7.2.4. Diabetes
7.2.5. Others
Chapter 8. Live Biotherapeutic Products And Microbiome Contract Manufacturing Market Segmentation 6: Regional Estimates & Trend Analysis
8.1. North America
8.1.1. North America Live Biotherapeutic Products And Microbiome Contract Manufacturing Market revenue (US$ Million) estimates and forecasts By Type of Services, 2021-2034
8.1.2. North America Live Biotherapeutic Products And Microbiome Contract Manufacturing Market revenue (US$ Million) estimates and forecasts By Scale of operations, 2021-2034
8.1.3. North America Live Biotherapeutic Products And Microbiome Contract Manufacturing Market revenue (US$ Million) estimates and forecasts by Application, 2021-2034
8.1.4. North America Live Biotherapeutic Products And Microbiome Contract Manufacturing Market revenue (US$ Million) estimates and forecasts by country, 2021-2034
8.2. Europe
8.2.1. Europe Live Biotherapeutic Products And Microbiome Contract Manufacturing Market revenue (US$ Million) By Type of Services, 2021-2034
8.2.2. Europe Live Biotherapeutic Products And Microbiome Contract Manufacturing Market revenue (US$ Million) By Scale of operations, 2021-2034
8.2.3. Europe Live Biotherapeutic Products And Microbiome Contract Manufacturing Market revenue (US$ Million) estimates and forecasts by Application, 2021-2034
8.2.4. Europe Live Biotherapeutic Products And Microbiome Contract Manufacturing Market revenue (US$ Million) by country, 2021-2034
8.3. Asia Pacific
8.3.1. Asia Pacific Live Biotherapeutic Products And Microbiome Contract Manufacturing Market revenue (US$ Million) By Type of Services, 2021-2034
8.3.2. Asia Pacific Live Biotherapeutic Products And Microbiome Contract Manufacturing Market revenue (US$ Million) By Scale of operations, 2021-2034
8.3.3. Asia Pacific Live Biotherapeutic Products And Microbiome Contract Manufacturing Market revenue (US$ Million) estimates and forecasts by Application, 2021-2034
8.3.4. Asia Pacific Live Biotherapeutic Products And Microbiome Contract Manufacturing Market revenue (US$ Million) by country, 2021-2034
8.4. Latin America
8.4.1. Latin America Live Biotherapeutic Products And Microbiome Contract Manufacturing Market revenue (US$ Million) By Type of Services, (US$ Million) 2021-2034
8.4.2. Latin America Live Biotherapeutic Products And Microbiome Contract Manufacturing Market revenue (US$ Million) By Scale of operations, (US$ Million) 2021-2034
8.4.3. Latin America Live Biotherapeutic Products And Microbiome Contract Manufacturing Market revenue (US$ Million) estimates and forecasts by Application, 2021-2034.
8.4.4. Latin America Live Biotherapeutic Products And Microbiome Contract Manufacturing Market revenue (US$ Million) by country, 2021-2034
8.5. Middle East & Africa
8.5.1. Middle East & Africa Live Biotherapeutic Products And Microbiome Contract Manufacturing Market revenue (US$ Million) By Type of Services, (US$ Million) 2021-2034
8.5.2. Middle East & Africa Live Biotherapeutic Products And Microbiome Contract Manufacturing Market revenue (US$ Million) By Scale of operations, (US$ Million) 2021-2034
8.5.3. Middle East & Africa Live Biotherapeutic Products And Microbiome Contract Manufacturing Market revenue (US$ Million) estimates and forecasts by Application, 2021-2034
8.5.4. Middle East & Africa Live Biotherapeutic Products And Microbiome Contract Manufacturing Market revenue (US$ Million) by country, 2021-2034
Chapter 9. Competitive Landscape
9.1. Major Mergers and Acquisitions/Strategic Alliances
9.2. Company Profiles
9.2.1 Quay Pharmaceuticals,
9.2.2 Cerbios-Pharma SA,
9.2.3 List Biological Labs, Inc.,
9.2.4 Arranta Bio (Acquired by Recipharm),
9.2.5 BacThera,
9.2.6 Biose Industrie
9.2.7 Wacker Biotech,
9.2.8 Other prominent players
Global Live Biotherapeutic Products and Microbiome Contract Manufacturing Market Based on Type of Services
Global Live Biotherapeutic Products and Microbiome Contract Manufacturing Market Based on Scale of Operation
Global Live Biotherapeutic Products and Microbiome Contract Manufacturing Market Based on Application
Global Live Biotherapeutic Products and Microbiome Contract Manufacturing Market Based on Region
Europe
North America
Asia Pacific
Latin America
Middle East & Africa